Two years ago South African company MJ MEDTECH a subsidiary of WUHAN GENERAL GROUP INC. announced plans to enter psychedelic sector after successful cannabis and CBD endeavors. Tests are now complete for rat and cell line trials, with the focus now being pushed towards analyzing the data and putting it into meaningful words that can show the true applications of psilocybin, which is produced by specific types of mushrooms that originate from spores. They are testing for brain chemistry, inflammation, overall health and long term affects. The goal of these studies is to prove the efficacy of psilocybin as a treatment for mental health (ptsd, depression, anxiety, etc) as well as other physical ailments (high blood pressure, brain inflammation etc). Human trials are now being scheduled in accordance with Covid 19 limitations. They currently have several successful cannabis products and will follow suit with extracts and fruiting bodies when testing is complete.
Related Articles
Forage to Feast: Exploring the Biology and Culinary Magic of Morel Mushrooms
It’s a mild spring day, with the warm sun casting flecks of light on the forest floor. Deciduous tree branches tangle together overhead and close in around a grassy depression, likely the remnant of a past disruption or abandoned pathway. The mushroom forager...
The Mushroom of Immortality: Learn About Medicinal Reishi Mushrooms
Reishi, along with the entire Ganoderma Genus, is prized for its health benefits, and is among the most unique-looking fungi in our collection. In this article, we’ll discuss some of the health benefits of Reishi mushrooms and Ganoderma as a whole. We’ll also discuss...
Washington’s New Psilocybin Therapy Bill & The Future of Legal Mushrooms
At the beginning of this year, Senator Jesse Salomon along with thirteen co-sponsors, filed Senate Bill 5201. This bill would allow for psilocybin-assisted therapy in Washington State. If passed, it would structure regulations for licensed therapeutic programs using...